United States securities and exchange commission logo

                            December 1, 2020

       Nima M. Farzan
       President and Chief Executive Officer
       Kinnate Biopharma Inc.
       11875 El Camino Real, Suite 101
       San Diego, California 92130

                                                        Re: Kinnate Biopharma
                                                            Amendment No. 1 to
Statement on Form S-1
                                                            Filed November 30,
                                                            File No. 333-250086

       Dear Ms. Farzan:

               We have reviewed your amended registration statement and have
the following
       comment. Please respond to this letter by amending your registration
statement and providing
       the requested information. If you do not believe our comment applies to
your facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your

              After reviewing any amendment to your registration statement and
the information you
       provide in response to the comment, we may have additional comments.

       Amendment No. 1 to Registration Statement on Form S-1

       Use of Proceeds, page 82

   1.                                                   We reissue comment 2.
Revise to state how much of the proceeds of the offer will be
                                                        used to "initiate and
complete [y]our planned Phase 1 clinical trial of KIN002787," how
                                                        much will be used to
"initiate [y]our planned Phase 1 clinical trial of KIN003," what
                                                        additional funds will
be needed to complete the Phase 1 trial of KIN003, and what portion
                                                        of the proceeds will go
to other RAF product candidates, other FGFR product candidates,
                                                        and other uses.
 Nima M. Farzan
FirstName LastNameNima
Kinnate Biopharma  Inc. M. Farzan
December  NameKinnate
             2020        Biopharma Inc.
Page 2    1, 2020 Page 2
FirstName LastName
        You may contact Julie Sherman at (202) 551-3640 or Angela Connell at
(202) 551-
3426 if you have questions regarding the financial statements and related
matters. Please contact
Abby Adams at (202) 551-6902 or Celeste Murphy at (202) 551-3257 with any other


                                                            Division of
Corporation Finance
                                                            Office of Life
cc:      Tony Jeffries, Esq.